Immunology of Factor VIII Inhibitors

ABSTRACT

Why some patients with hemophilia A produce inhibitory antibodies is not known. However, many new findings both in the mechanisms of immune tolerance and in the understanding of the mechanisms by which antibodies interact with the factor VIII molecule are converging toward an integrated picture of what tolerance to factor VIII represents. The latter results from a subtle equilibrium among all partners of the immune system that is actively maintained. Circumstances under which such an equilibrium is disrupted are now better understood. The anti-factor VIII response can now be analyzed at the clonal level (both B and T levels), which allows us to test a number of hypotheses on both the prevention and the treatment of factor VIII inhibitors.

Hemophilia A - factor VIII - tolerance - antibodies - inhibitors

REFERENCES

• 1 Gilles J GG, Saint-Remy J MR. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.  J Clin Invest . 1994;  94 1496-1505
• 2 Saint-Remy J MR. B and T cell tolerance: from basic concepts to clinical practice.  Haematologica . 2000;  85(Suppl 10) 93-96
• 3 Jacquemin M G, Vanzieleghem B, Saint-Remy J MR. Mechanisms of B-cell tolerance. In: Monroe DM, Hedner U, Hoffman MR, et al., eds. Proceedings, Hemophilia Care for the New Millenium Symposium Chapel Hill, North Carolina: Kluwer Academic/Plenum 1999: 99-108
• 4 Reipert B M, Ahmad R U, Turecek P L, Schwarz H P. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia.  Thromb Haemost . 2000;  84 826-832
• 5 Scandella D H. Properties of anti-factor VIII antibodies in hemophilia A patients.  Semin Thromb Hemost . 2000;  26 137-142
• 6 Jacquemin M G, Benhida A, Peerlinck K. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.  Blood . 2000;  95 156-165
• 7 Spiegel P C, Jacquemin M G, Saint-Remy J MR. Crystal structure of the factor VIII C2 domain complexed with the Fab fragment of a factor VIII inhibitor antibody (Abst).  Blood . 2000;  96 489
• 8 Gilles J GG, Arnout J, Vermylen J, Saint-Remy J MR. Anti-factor VIII antibodies of haemophiliac patients are directed primarily towards non-functional determinants and do not exhibit isotypic restriction.  Blood . 1993;  82 2452-2461
• 9 Jacquemin M, Burny W, Vantomme V. High levels of IFNgamma production by FVIII-specific T cells from a mild/moderate hemophilia A patient with inhibitor (Abst).  Blood . 2000;  96 489
• 10 Barrow R T, Healey J F, Jacquemin M G. Antigenicity of putative phospholipid membrane binding residues in factor VIII.  Blood . 2001;  97 169-174
• 11 Qian J, Burkly L C, Smith E P. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer.  Eur J Immunol . 2000;  30 2548-2554
• 12 Gilles J G, Desqueper B, Lenk H. Neutralizing anti-idiotypic antibodies to factor VIII inhibitors following desensitization in patients with hemophilia A.  J Clin Invest . 1996;  97 1382-1388
• 13 Vanzieleghem B, Gilles J G, Desqueper B. Humanized severe combined immunodeficient mice as a potential model for the study of tolerance to factor VIII.  Thromb Haemost . 2000;  83 833-839